Scopio Labs News
19 articles
/PRNewswire/ -- Scopio Labs announced today its strategic alliance with Siemens Healthineers has expanded to include the global distribution of Scopio's...
Scopio Labs has announced an expanded strategic alliance with Siemens Healthineers to globally distribute its Full-Field Bone Marrow Aspirate (FF-BMA) Application, a digital solution for bone marrow aspirate review. This technology addresses the challenges faced by clinical laboratories, such as staffing shortages and the need for remote access to results. The FF-BMA solution, which includes AI-powered decision support and remote review capabilities, aims to optimize lab workflows and enhance diagnostic confidence. The partnership builds on the existing distribution of Scopios X100 and X100HT imaging platforms. Scopio Labs applications are FDA-cleared and CE-marked, although the FF-BMA Application is not yet available in the US for in vitro diagnostic procedures.
Partners
Scopio Labs secures $42 million Series D for AI-based blood cell analysis | CTech
Scopio Labs, an Israeli startup that develops full-field digital cell morphology imaging and analysis platforms, has raised $42 million in a Series D funding round. The round was led by Fortissimo Capital, with participation from existing investors. The funds will be used to expand the companys customer base and complete the development of another analysis tool for blood tests. Scopios platform uses computational photography to provide digital imaging of thousands of cells, enhancing workflow efficiency in blood cell analysis and bolstering patient care.
InvestmentExpand
Scopio Labs's digital bone marrow aspirate application receives FDA clearance - GlobalData
Scopio Labs has received De Novo clearance from the US Food and Drug Administration for its Full-Field Bone Marrow Aspirate (FF-BMA) Application. The clearance will expedite the transition to AI-powered digital hematopathology, enhancing diagnostic speed and patient care. The FF-BMA Application will transform BMA analysis with a fully digital workflow that integrates with Scopios X100 and X100HT platforms. The application will aid in critical evaluations such as assessing the quality of bone marrow smears, estimating the number of blast and plasma cells, and calculating the myeloid to erythroid ratio. Siemens Healthineers will serve as the distributor for Scopio Labs’s Scopio X100 and Scopio X100HT imaging platforms worldwide.
CustomersPartners
Beckman Coulter Connects Scopio Labs Digital Cell Morphology with Hematology Workcell Extending Automated Workflow
Beckman Coulter, a global leader in clinical diagnostics, has announced a partnership with Scopio Labs to debut its hematology analyzer and slidemaker stainer connected to Scopio Labs digital morphology platform. This platform uses artificial intelligence-assisted peripheral blood smear analysis, which will be showcased at the 2023 American Association for Clinical Chemistry (AACC) Annual Scientific Meeting and Clinical Lab Expo. The partnership aims to improve lab efficiency by automating hematology workflow and advancing the future of complete blood count tests.
Partners
Scopio Labs lands multi-million deal with Siemens for digital cell morphology tech | CTech
Israeli startup Scopio Labs has signed strategic cooperation deals with Siemens Healthineers and Beckman Coulter. The deals are expected to generate tens of millions of dollars in revenue for Scopio Labs in the coming years. Scopio Labs technology allows clinical laboratorians to examine patient blood cell samples digitally, offering high-resolution viewing and remote capabilities. The companys digital cell morphology platforms are intended for use in central laboratories.
Partners
Scopio Labs Doubles Down on Digital Cell Morphology Go-To-Market Strategy in 2023
Scopio Labs announced that it will focus on the commercialization of its laboratory diagnostic solutions in 2023 to accelerate market penetration and growth. The company has appointed Amir Farhi as its Chief Commercial Officer to oversee the development and execution of the commercial strategy. Farhi brings over 30 years of experience in sales, marketing, strategic alliances, and operations. Scopio Labs has also signed a global distribution agreement with Beckman Coulter, a global leader in clinical diagnostics. The company aims to completely digitize the hematology laboratory with its Full-Field Cell Morphology™ technology. Scopio Labs has experienced a significant increase in revenue and is focused on scaling its go-to-market execution to accelerate global reach.
Partners
Not under the microscope: Scopio Labs transforms blood testing | CTech
Israeli medtech startup Scopio Labs is working to make microscopes used in blood testing labs obsolete. The company, founded in 2015, has developed a scanner that digitizes glass slides and applies deep learning and computer vision to analyze them. Scopios solution provides a comprehensive workflow that enables remote work and uses AI to count and classify cells, providing more consistent results. The company has raised $85 million to date and its FDA-cleared, CE-marked Full-Field Peripheral Blood Smear application is in commercial use across the US and Europe. Scopio Labs has experienced growth during the pandemic, as the global understanding of the importance of healthcare and the need for remote solutions increased. The company sees Israel as a leader in the medtech field, particularly in the application of AI to medical imaging.
CustomersExpand
Scopio Labs Launches World's First Digital Application for Bone Marrow Aspirate Imaging and Review
Scopio Labs has launched the Full-Field Bone Marrow Aspirate (FF-BMA) Application, which utilizes AI and imaging to provide a complete digital workflow for bone marrow aspirate scanning and analysis. The application allows for remote analysis over a secure hospital network, eliminating the need for manual microscopy. Scopios technology overcomes the limitations of manual analysis and provides a comprehensive analysis of bone marrow samples. The company aims to bring digital transformation to hematopathology and enhance the capabilities of physicians. The FF-BMA Application operates on Scopios existing devices and offers a scalable solution for digitizing hematology diagnostics and testing processes.
Customers
Scopio Labs Awarded FDA Clearance for High Throughput Hematology Digital Cell Morphology Platform, Replacing Microscopes with Digitization
Scopio Labs has received FDA 510(k) clearance for its X100HT device with Peripheral Blood Smear (PBS) Application. This clearance allows Scopio to broaden its suite of fully digital platforms for earlier and more accurate detection of cancers, infections, and other diseases. The X100HT device caters to major medical facilities and labs worldwide, offering high throughput capabilities and the highest resolution for hematological analysis. The device eliminates the need for additional manual microscopic examination and supports remote review capabilities, enabling telehematology. Scopio Labs aims to accelerate PBS analysis, improve consistency of results, and reduce review time with its AI-powered diagnostic platforms.
Customers
Digital Microscope Streamlines The Search For Cell Abnormalities In Blood
Israeli company Scopio Labs has developed a digital imaging platform that uses computational photography and AI to digitize and analyze cell samples with ultra-high resolution. The platform aims to streamline the process of blood analysis, making it easier and more precise to identify potential cell abnormalities. Scopio Labs recently raised a $50 million Series C round to further develop the diagnostic imaging tool. The company has received FDA clearance and a CE mark for its X100 Microscope and Decision Support System, allowing it to be used in laboratories across the US and Europe. The technology has the potential to enhance the efficiency of medical staff and revolutionize the field of medicine.
Customers
Scopio Labs raises $50 million Series C for digital microscope
Israeli startup company Scopio Labs, developer of a digital microscope, has raised $50 million in a Series C funding round. The company plans to use the investment to double its number of employees and expand strategic development, sales, and partnerships. Scopio Labs digital microscope revolutionizes the field of hematology by creating new information through advanced computational photography technology. The device allows for fast scans of large surfaces at the highest resolution in the world. The companys technology enables complete digitization of blood samples, providing a digital file that can be analyzed remotely. The unique digital information also allows for the integration of AI-based decision-support tools. Scopio Labs flagship product is approved by the U.S. FDA and the European CE and is being used in hematology laboratories worldwide. The investment was led by a strategic partner from the pharma world, along with other strategic investors.
InvestmentExpand
Scopio Labs Launches Full-Field Peripheral Blood Smear Application, Bringing End-to-End Digital Workflow to Hematology Labs to Transform Diagnostic Testing
Scopio Labs has announced the commercial launch of its Full-Field Peripheral Blood Smear (FF-PBS) Application, a digital solution for cell morphology analysis in hematology. The application offers full-field imaging and an AI-powered Decision Support System, streamlining workflows and optimizing the blood smear analysis process. It provides lab practitioners with a full-field view of cells at 100X magnification, allowing for confident clinical decision-making. The application features adaptive monolayer identification, WBC detection, RBC morphology evaluation, and automated platelet location. Using Scopios FF-PBS Application reduces turnaround time for sample reviews by 60%. The browser-based true remote solution enables offsite colleagues and clinicians to securely review and collaborate. Scopios technology has already been implemented at hospitals and labs in the US, Europe, and Israel.
Customers
Israeli startup Scopio Labs gets FDA' stamp of approval for AI microscope diagnostics
Israeli startup Scopio Labs has received FDA clearance to market its X100 product with Full Field Peripheral Blood Smear (Full Field PBS) Application. The companys AI-powered digital microscopy system provides clinical laboratories with the ability to capture digital scans of blood samples at a 100X oil immersion resolution level. This technology aims to improve the quality of care, consistency of results, and reduce review time for hematology labs. Scopio Labs previously closed a $16 million Series B funding round, bringing its total funding to $30 million.
Customers
https://www.jpost.com/health-science/hillels-tech-corner-ai-meets-telescopy-at-scopio-labs-628070
Scopio Labs, a Tel Aviv-based start-up, is revolutionizing microscopy with its machine learning-based digital microscopy system. The companys products and platforms improve standard processes, reduce human error, and increase efficiency in diagnostic labs. Scopio Labs recently raised $16 million in a Series B round, bringing its total funding to $30 million. The companys market-ready product integrates with existing systems and has gained traction in veterinary medicine. It allows for remote collaboration and rapid scanning of full-slide images, digitizing slides and generating comprehensive reports. Scopio Labs is now focusing on expanding its commercial rollout in the United States and Europe.
CustomersPartners
Scopio Labs and SYNLAB's Veterinary Pathology Group Partner to Bring First In-practice Digital Cytology Solution to the UK
Scopio Labs and SYNLAB UK & Irelands Veterinary Pathology Group (VPG) have signed an exclusive distribution partnership agreement. VPG will offer customers in the UK and Ireland the ScopioVet Digital Cytology System, providing 24/7 access to clinical pathologists for results within 1 hour. This partnership marks Scopios global expansion into the UK and Ireland. ScopioVet is a powerful digital cytology platform that allows veterinary hospitals to scan and send high-resolution digital images for analysis by clinical pathologists. The first scanners are already being installed in top referral practices and are available to veterinary practices across the UK and Ireland.
PartnersCustomers
Israeli digital microscopy co Scopio Labs raises $16m
Scopio Labs, an Israel-based digital microscopy company, has completed a $16 million Series B financing round led by Olive Tree Ventures. The funding brings the total raised by the company to $30 million. The new funds will be used to expand commercial operations in the US and Europe, accelerate manufacturing and sales, and develop a clinical trial pipeline. Scopio Labs has developed a digital platform that automates the imaging of full microscopy samples into high-resolution digital scans. The company recently received a CE mark certification for its X100 Full Field Peripheral Blood Smear (PBS) microscopy system and has launched ScopioVet, a digital cytology solution for veterinary professionals.
InvestmentExpand
Scopio Labs Receives CE Mark for X100 Microscope and Decision Support System With Full Field Peripheral Blood Smear (PBS) Application
Scopio Labs has received CE mark certification for its X100 Full Field Peripheral Blood Smear (Full Field PBS) all-digital morphology analysis platform. The platform allows for remote consultation and includes a computer-vision based decision support system. Scopio Labs aims to bring the digital revolution into the laboratory and improve the outcome of care across medicine. The Full Field PBS system offers an end-to-end decision-support tool for clinicians, providing high-resolution scans and data summaries that can be reviewed remotely. The company plans to provide additional assistive tools for hematology diagnostics and unlock new capabilities for the industry.
Customers
Scopio Labs Advances Digital Cytology Through Launch of Automated, High-Resolution Imaging and Decision-Support Solutions for Veterinary Market
Scopio Labs has announced the commercial availability of its ScopioVet Digital Cytology System in the United States and Canada. The system offers an end-to-end solution for veterinary digital cytology, including a proprietary microscopy imaging system, pathology consultation service, and AI tools for diagnostic tests. ScopioVet allows veterinary clinics to scan and send cytology and hematology cases to a network of clinical pathologists for analysis within one hour. The system provides high-resolution imaging and features such as a three-slide tray and in-app pathologist chat. Scopio Labs is also developing AI tools to enhance accuracy and efficiency. The company aims to digitize and improve the veterinary diagnostic process. The article does not mention any specific partners, investors, or customers.
CustomersPartners
Digital microscopy co Scopio Labs raises $7m
Scopio Labs, an Israeli company that develops advanced digital microscopy and platform, has closed a $7 million financing round from investors including OurCrowd. The funds will be used to expand the team and hire computer vision experts, physicists, and software developers. OurCrowd CEO Jon Medved expressed excitement about the investment and stated that Scopio Labs is revolutionizing digital microscopy. This investment marks OurCrowds 23rd healthtech investment, bringing their total investment in the sector to $80 million.
InvestmentExpand
